[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anorexia-nervosa-restricting-type\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anorexia-nervosa-restricting-type":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,64,99,129,159,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":35,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":52,"lastUpdatePostDateStruct":53,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":63},"100648767","3-dimensional-optical-scanning-to-assess-and-monitor-malnutrition-in-eating-disorders-3d-ed-study-100648767",false,"NCT07726524","3-Dimensional Optical Scanning to Assess and Monitor Malnutrition in Eating Disorders (3D-ED) Study","3D-ED","Inclusion Criteria:\n\n* Diagnosis of anorexia nervosa (AN) or atypical anorexia nervosa (AAN), restricting or purging subtype, per DSM-5\n* Age 15 to 26 years\n* Medical instability warranting an inpatient hospitalization defined by either:\n\n  1. vital signs: daytime heart rate below 50 bpm or nighttime heart rate below 45 bpm, blood pressure below 90\u002F50 mm Hg, temperature below 36 C, orthostatic increase in heart rate above 20 bpm or decrease in systolic blood pressure above 20 mm Hg or decrease in diastolic blood pressure above 10 mm Hg from lying to standing, or median BMI below 75 percent; or\n  2. laboratory abnormality: AST above 40 IU\u002FL, ALT above 30 IU\u002FL, estimated GFR below 90 or cystatin C below 0.7 mg\u002FL, albumin below 3.7 g\u002FdL, or prealbumin below 20 mg\u002FdL\n* Extreme AN is defined as BMI below 15 kg\u002Fm2 or serious medical complications warranting admission to ACUTE (Denver Site).\n\nExclusion Criteria:\n\n* Bulimia nervosa\n* Another primary diagnosis causing malnutrition (not an eating disorder)\n* Current active suicidality\n* Metal implants or devices that interfere with study procedures","ALL","15 Years","26 Years",{"count":20,"type":21},90,"ESTIMATED","OBSERVATIONAL","People with anorexia nervosa often become medically unstable because of severe malnutrition and require hospitalization for nutritional rehabilitation. Clinicians currently rely heavily on body weight to assess malnutrition, but body weight does not always reflect the severity of illness. This study will use infrared scanning to assess body composition in adolescents and young adults hospitalized with anorexia nervosa. Researchers will then examine how organ and tissue stores relate to the degree of malnutrition, predict nutritional needs and medical restoration in hospital, and recovery outcomes over the following year. The goal is to develop more individualized approaches to nutritional rehabilitation and improve recovery for individuals with malnutrition due to eating disorders.",[25,26,27,28,29,30,31,32,33,34],"Anorexia in Adolescence","Anorexia Nervosa","Anorexia Nervosa, Atypical","Anorexia Nervosa, Binge Eating\u002FPurging Type","Anorexia Nervosa Restricting Type","Anorexia Nervosa With Significantly Low Body Weight","Body Composition Changes","Growth & Development","Malnutrition Severe","Malnutrition, Calorie",[36,37,38,39,40,41,42,43,44,45,46,47,48,49,50],"Organ residual mass","Body composition","Three-dimensional optical imaging","Optical body scanning","Refeeding","Refeeding syndrome","Nutritional rehabilitation","Resting energy expenditure","Eating disorders","Bioelectrical impedance analysis","Fat-free mass","Adolescent","Young adult","Anorexia nervosa","Growth charts","NOT_YET_RECRUITING","2026-07-22",{"date":54,"type":55},"2026-07-24","ACTUAL",{"date":57,"type":21},"2027-01",{"date":59,"type":21},"2031-05",{"name":61,"class":62},"University of California, San Francisco","OTHER",2,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100561684","fecal-microbiota-transplant-for-anorexia-nervosa-100561684","NCT06593366","Fecal Microbiota Transplant for Anorexia Nervosa","A Pilot Feasibility Randomized Controlled Trial of Fecal Microbiota Transplant for Adolescent Anorexia Nervosa","FMT-AN","Inclusion Criteria: All study subjects will have been diagnosed with AN (restricting type or binge eating\u002Fpurging type) by the primary physician on the ED team, as per standard approach. Study participants will:\n\n* Be 12-17 years-old at time of recruitment\n* Have capacity to consent\n* Be assigned female sex at birth (may be gender diverse)\n* Be active patients in the pediatric ED program at MCH\n* Have a weight that is \\\u003C85% of the Treatment Goal Weight, as determined by the treating physician\n\nExclusion Criteria: Potential study subjects will be excluded due to the following reasons:\n\n* Exposure to antibiotics within two weeks of study randomization\n* Initiation of new probiotics \u002F oral nutritional supplements within two weeks of randomization\n* Active pregnancy\n* Active psychosis or suicidal ideation\n* Other comorbidities that may affect weight or the gut microbiome including celiac disease, inflammatory bowel disease (or other conditions as determined by the study team)","FEMALE","12 Years","17 Years",{"count":76,"type":21},20,"INTERVENTIONAL",[79],"NA","The purpose of this pilot randomized-controlled trial is to determine whether Fecal Microbiota Transplant (FMT) treatment demonstrates feasibility, acceptability, and prelinary effectiveness among patients with anorexia nervosa (AN). Specifically, the investigators aim to compare changes in weight, gut microbiome, urine, blood biomarkers and mood symptoms between participants receiving the FMT intervention and placebo.",[29,26,25,82,83],"Anorexia in Children","Anorexia",[85,86,87,88,89],"anorexia nervosa","fecal microbiota transplant","pilot study","randomized controlled trial","feasibility","2026-05-22",{"date":92,"type":55},"2026-05-27",{"date":94,"type":21},"2026-06-01",{"date":96,"type":21},"2027-06-01",{"name":98,"class":62},"Hamilton Health Sciences Corporation",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100570841","biomarkers-in-ev-associated-with-marrow-adiposity-in-anorexia-100570841","NCT06712485","Biomarkers in EV Associated With Marrow Adiposity in Anorexia","Identification of Biomarkers in Extracellular Vesicles Associated With Marrow Adiposity and Bone Deterioration Caused by Nutritional Deficiencies","VE_BMAT_AN","Inclusion Criteria:\n\nFor AN group:\n\n* Diagnosis of active AN according to DSM-5 criteria\n* BMI of less than 17kg\u002Fm2\n* Present amenorrhoea in the 3 months prior to the start of the study.\n\nFor AN-R group:\n\n* Achieved weight gain of more than 85%.\n* Normal menstruation in the last 3 months.\n\nFor Control group:\n\n* Population of the same age and gender as the AN and AN-R groups.\n* If pubertal population, presenting a chronological age of ± 2 years.\n* Normal menstruation\n* Normal BMI (\\>18.5 kg\u002Fm2)\n* No presence of previous dietary transtrons.\n\nExclusion Criteria:\n\n* Not receiving oestrogens, contraceptives or glucocorticoids in the 3 months prior to the start of the study.\n* Not to suffer from chronic diseases, such as diabetes, pathologies affecting the bone system or thyroid function.\n* Do not take calcium or vitamin supplements.",true,{"count":109,"type":21},30,"The aim of this observational study is to identify biomarkers in extracellular vesicles associated with medullary adiposity occurring in patients with anorexia nervosa. The main question it aims to answer is:\n\nCan this medullary adiposity be associated with the bone deterioration observed in this population?\n\nParticipants will be assessed for body composition and a blood sample will be taken by non-invasive techniques.",[29,112],"Anorexia Nervosa (DSM-IV Revised Criteria)",[114,115,116,117,118],"Extracellular Vesicles","Bone Deterioration","Biomarkers","Bone Marrow Adipose Tissue","Nutritional Deficiencies","2025-05-05",{"date":121,"type":55},"2025-05-07",{"date":123,"type":21},"2025-05-15",{"date":125,"type":21},"2026-07-31",{"name":127,"class":62},"Maimónides Biomedical Research Institute of Córdoba",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":107,"sex":16,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":143,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":128},"100507310","novel-targetable-biomarkers-in-anorexia-nervosa-100507310","NCT05885724","Novel Targetable BIOmarkers in ANorexia NervosA","Novel Targetable BIOmarkers in ANorexia NervosA - BIOANNA","BIOANNA","N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, non-exercising subtype\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 10-16 kg\u002Fm2\n\nN=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study.\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 10-16 kg\u002Fm2\n\nN=16 control participants, sex- and age-matched to the individual anorexia nervosa patients.\n\nInclusion criteria:\n\n* Age 18-60 years\n* Written informed consent\n* BMI 19-24.9 kg\u002Fm2\n\nExclusion Criteria:\n\n* Use of antibiotics within the last 31 days\n* Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption (≤ 24 g of alcohol per day allowed)\n* Any kind of severe chronic disease other than AN (e.g. active cancer disease)\n* Severe renal impairment (e.g. estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002Fm2) if resulting from another disease than AN\n* Known liver cirrhosis or other severe liver impairment if resulting from another disease than AN\n* Acute upper respiratory tract infection within the last 31 days\n* Uncontrolled dysthyroidism\n* Uncontrolled hypertension\n* Current pregnancy\u002Flactation or current treatment for in vitro fertilization\n* Inability to understand the study information, to sign the consent form and to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.","18 Years","60 Years",{"count":140,"type":21},32,"The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.",[26,29],[144,145,146,147,148],"exercising subtype","non-exercising subtype","Neurofilament light chain","Glial fibrillary acidic protein","Growth Differentiation Factor-15","RECRUITING","2024-12-06",{"date":152,"type":55},"2024-12-12",{"date":154,"type":55},"2023-05-01",{"date":156,"type":21},"2025-04-30",{"name":158,"class":62},"University Hospital, Basel, Switzerland",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":72,"minAge":137,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":77,"phases":170,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":51,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100568957","phase-2-acetylcholinesterase-inhibitor-in-anorexia-nervosa-multicenter-double-blind-placebo-controlled-trial-100568957","NCT06687993","Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial","Acetylcholinesterase Inhibitor Treatment in Anorexia Nervosa: a Multicenter, Double-Blind, Placebo-Controlled Randomized Trial","ANACh","Inclusion Criteria:\n\n* Female\n* Presence of the 3 DSM-V criteria for Anorexia Nervosa\n* Restrictive subtype of Anorexia Nervosa according to DSM-5\n* Body Mass Index between 15 and 18.5 kg\u002Fm²\n* Aged 18 to 65 years\n* Resting heart rate \\> or = 40 bpm\n* Use of a highly effective contraceptive method\n* Affiliation or entitlement to a Health Insurance scheme\n* Prior free, informed, and written consent\n\nExclusion Criteria:\n\n* Presence of one or more somatic criteria for hospitalization according to french HAS 2010 guidelines\n* Past diagnosis of anorexia nervosa with binge-eating\u002Fpurging type\n* Past diagnosis of bulimia nervosa\n* Past diagnosis of binge-eating disorder\n* Associated diagnosis of schizophrenia and\u002For persistent delusional disorder and\u002For bipolar disorder\n* History of asthma or obstructive bronchopulmonary disease\n* History of peptic ulcer disease or concurrent treatment with non-steroidal anti-inflammatory drugs\n* History of epileptic disorders\n* Renal insufficiency (glomerular filtration rate less than 60 mL\u002Fmin according to the MDRD formula)\n* Hepatic insufficiency or transaminase levels greater than 5 times the normal upper limit\n* Conductance disorder characterized by electrocardiogram\n* QTc according to Bazett's formula greater than 480 ms on electrocardiogram\n* Current or recent (within three weeks prior to inclusion) psychotropic treatment (including antidepressants, to avoid interaction\u002Fpotentiation in this population)\n* Treatment involving the following cytochromes: P450, P3A4, P2D6\n* Known hypersensitivity to donepezil hydrochloride, piperidine derivatives, or any excipients of the investigational drug\n* Pregnant or breastfeeding woman\n* Person under legal protection measures\n* Person under guardianship measures","65 Years",{"count":169,"type":21},147,[171],"PHASE2","The goal of this clinical trial is to learn if the daily take of donepezil can treat adult patient suffering from anorexia nervosa. The main question it aims to answer is : do daily donepezil intake permit weight gain and reduction of food restriction rituals ? The treatment is a capsule comprising a drug limiting the degradation of a neurotransmitter called acetylcholine. This treatment has long been used to treat certain cognitive disorders. Researchers will compare two drug dosage and a look-alike capsule that contains no drug to see if the dose has an impact on the effect. Participants will take one capsule per day for three months will have regular hospital visits for cognitive and metabolic tests.",[29],[85,175,176,177],"eating disorders","donepezil","habits","2024-11-12",{"date":180,"type":55},"2024-11-14",{"date":182,"type":21},"2024-11",{"date":184,"type":21},"2030-05",{"name":186,"class":62},"Centre Hospitalier St Anne",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":107,"sex":72,"minAge":137,"maxAge":167,"enrollmentInfo":195,"targetDuration":4,"studyType":77,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":128},"100519966","radically-open-dialectical-behaviour-therapy-in-patients-with-anorexia-nervosa-100519966","NCT06050421","Radically Open Dialectical Behaviour Therapy in Patients With Anorexia Nervosa","Evaluating the Efficacy of Radically Open Dialectical Behaviour Therapy (RO-DBT) in Patients With Anorexia Nervosa: a Randomized Controlled Clinical Trial","RODBT-AN","Inclusion Criteria:\n\n* female patients\n* aged between 18 to 65 years old,\n* having a diagnosis of AN (DSM 5 criteria),\n* having had weigh restoration treatment (normal BMI considered \\>19 kg\u002Fm2)\n* having an overcontrol personality style assessed with the styles of coping Word-Pair Checklist scale (ASC-WP)\n\nExclusion Criteria:\n\n* diagnosis of severe mental illness (schizophrenia or other psychosis, bipolar disorder, major depressive disorder, substance use disorder)\n* diagnosis of borderline personality disorder (BPD) or positive result in McLean Screening Instrument for BPD\n* mental retardation\n* being under standardized psychotherapy at the baseline\n* being illiterate or not able to understand Spanish language,\n* being left-handed\n* being pregnant for MRI requirements.",{"count":196,"type":21},96,[79],"Randomized controlled clinical trial to evaluate the efficacy of \"Radically Open Dialectical Behaviour Therapy\" in patients with eating disorders: a proof-of-concept study.",[26,200,29],"Anorexia Nervosa in Remission",[202],"anorexia nervosa, RODBT","2023-09-15",{"date":205,"type":55},"2023-09-22",{"date":207,"type":55},"2023-06-22",{"date":209,"type":21},"2026-06-30",{"name":211,"class":62},"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau"]